ALTSTATION.IO

Incyte Corporation (INCY) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$106.51

Change

+3.65%

Market Cap

$20.91B

Avg Volume

2.0M

Company Overview

Incyte Corporation is a biopharmaceutical company based in Wilmington, Delaware. It focuses on developing and selling innovative therapies in the healthcare sector, specifically targeting various cancers and serious autoimmune conditions. Their key products include JAKAFI for myelofibrosis and acute graft-versus-host disease, MONJUVI for lymphoma, and PEMAZYRE for biliary tract cancer. They distribute these therapies through specialty pharmacies, retail pharmacies, and hospital systems primarily in the U.S., Europe, Canada, and Japan.

Incyte is positioned as a significant player within the biotechnology field, notably with JAKAFI being their flagship product that generated revenues of $1.6 billion in 2022 alone. The company faces competition from large biotech firms like Celgene and AbbVie, especially in the oncology space. This competitive landscape pressures Incyte to innovate continually, as patents on key products like JAKAFI approach expiration, which could open the door for generics.

Currently, Incyte is in a growth phase, bolstered by recent strategic shifts towards expanding its pipeline and collaborations, such as with Genesis Therapeutics. The introduction of new therapies, including those targeting solid tumors and chronic skin conditions, signals a pivot toward diversifying their offerings. Their commitment to innovation, alongside strong sales from existing products, positions Incyte to maintain relevance in a rapidly changing biotech environment.

Key Financials

Market Cap

$20.91B

Revenue

$4.81B

EBITDA

$1.32B

Gross Margin

56.5%

Profit Margin

24.7%

Revenue Growth

20.0%

Total Cash

$2.93B

Total Debt

$41.27M

Free Cash Flow

$531.25M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

18.05

Forward P/E

13.38

Beta

0.85

52-Week High

$112.29

52-Week Low

$53.56

EPS

$5.90

50-Day Avg

$101.86

200-Day Avg

$84.23

Price/Book

4.49

Technical Analysis

Over the past 52 weeks, Incyte Corporation (INCY) has demonstrated a strong upward trend, with the stock appreciating by 58.7% to its current price of $106.51. The primary support level can be identified around $70, where the stock found multiple bounces, while a key resistance level is just below $108.39, which has shown to halt the upward momentum in recent trading. Notably, the chart reveals a series of higher highs and higher lows, indicative of a bullish market sentiment. In the last few weeks, momentum appears to have picked up as the price approaches the resistance level, suggesting an intensifying interest among buyers. At its current price, INCY is within striking distance of its 52-week high, indicating bullish potential; however, it also suggests a possible consolidation or pullback if it fails to break through the resistance.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Incyte Corporation (INCY) stock in the past week (February 1-7, 2026):

Market Update

### **Incyte’s Zynyz Receives Positive EU Regulatory Opinion for Anal Cancer**
Incyte announced on February 1, 2026, that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of Zynyz (retifanlimab) in combination with chemotherapy for the first-line treatment of advanced squamous cell carcinoma of the anal

Market Update

### **Analyst Initiates “Buy” Rating with Significant Price Target**
On February 5, 2026, HC Wainwright & Co. initiated coverage of Incyte Corporation (INCY) with a “Buy” recommendation and set a price target of $135.00. This new rating suggests a positive outlook on Incyte’s market performance and future potential from this analytical firm.

Market Sentiment and Analyst Recommendations

Bull Case

Incyte is firing on multiple cylinders right now. Revenue growth at 20% annually is solid for a $4.8B biotech, and the company just got a positive EU regulatory opinion for Zynyz in anal cancer, which expands an already-growing oncology franchise. The balance sheet is fortress-like with $2.93B in cash against only $41M in debt, giving management real flexibility to fund R&D and potential M&A. Management’s stated goal to nearly triple non-Jakafi revenue by 2029 is ambitious but credible given the pipeline momentum. At 18x forward P/E, the stock isn’t cheap, but it’s reasonable for a company growing at 20% with multiple shots on goal in immunology and oncology. The analyst crowd agrees: 22 buy ratings with targets ranging up to $135 suggest consensus sees 25%+ upside from here.

Bear Case

Incyte is heavily dependent on Jakafi, its flagship JAK inhibitor, and any competitive pressure or market saturation in that space would hurt. The stock has already run 58.7% over the past year and sits near its 52-week high of $112.29, meaning valuation has expanded alongside the price move. The analyst target range is wide ($70 to $135), which tells you there’s real disagreement on fair value despite the buy consensus. Macro risk exists too: biotech stocks are sensitive to interest rate moves and regulatory scrutiny, both of which could flare up. Execution risk on new product launches is always present in this industry. The upcoming Q4 earnings on February 10 will be critical; any miss on the $1.35B revenue guidance or weaker-than-expected guidance for 2026 could trigger a quick 5-10% pullback.

What to Watch

The Q4 earnings report on February 10 is the immediate catalyst. Watch for revenue confirmation around that $1.35B consensus and management’s 2026 guidance, especially on Zynyz trajectory and non-Jakafi revenue growth. The EU approval decision on Zynyz for anal cancer should come within the next few months; that’s a real revenue driver if it hits. Track the stock’s ability to break through $108.39 resistance; failure to hold that level could signal a pullback toward $100. Monitor pipeline updates at upcoming medical conferences and any competitive threats from other JAK inhibitors or checkpoint inhibitors in oncology. Watch for any M&A activity, since the strong balance sheet makes Incyte an acquirer candidate. Quarterly revenue growth rate is the key metric: if that 20% growth rate starts to decelerate below 15% in consecutive quarters, the bull thesis weakens materially.

Analyst Consensus

BUY

Based on 22 analyst opinions

Low Target

$70.00

Mean Target

$103.86

High Target

$135.00

Earnings and Financial Data

Sector

Healthcare

Industry

Biotechnology

Employees

2,617

Earnings & Dividends

Next Earnings

Feb 10, 2026

EPS (Trailing)

$5.90

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is INCY a good stock to buy?

Analysts rate Incyte Corporation (INCY) as a BUY with a target price of $103.86, suggesting some upside potential despite its current price of $106.51. Given its solid P/E ratio of 18.05 relative to the biotech sector, the stock appears reasonably valued for growth.

What is INCY’s price target?

The average analyst price target for INCY is $103.86. This target reflects expected valuations based on current performance and industry conditions, indicating that there may be minor downside risk from the current price.

Does INCY pay a dividend?

No, Incyte Corporation does not pay a dividend. Investors looking for income should consider this, as profits are likely being reinvested into research and development instead.

What is the 52-week range for INCY?

INCY’s 52-week trading range is between $53.56 and $112.29. This range indicates significant volatility, but the current price near the upper end suggests strong performance over the past year.

What is INCY’s market cap?

Incyte Corporation has a market cap of $20.91 billion. This sizable market cap positions it well within the healthcare sector, providing stability and attracting institutional investors.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.